Interleukin-17 is a favorable prognostic marker for colorectal cancer

Lin, Ying; Xu, Jing; Su, Hang; Wu, Zhong; Yao, Yuan; Zhong, Yu; Yu, Fang; Zhou, Huaqiang; Li, C.; Huang, Kai

doi:10.1007/s12094-014-1197-3

Cited by 48 publications

(31 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Three more studies did not focus on IL-17 C tumor-infiltrating immune cells and are included with their reported correlations in Table 1 for completeness, but not in the quantitative analyses. 39,55,56 Collectively, 18 studies reported on a significant correlation between high IL-17 and poor prognosis, over 3.5 times more than the studies showing a correlation with improved prognosis (n D 5, Table 2). To visualize the overall correlation, forest plots are shown for the hazard ratio of a high number of IL-17 C cells on overall (OS) ( Fig.…”

Section: Study Design and Selection Criteriamentioning

confidence: 94%

The correlations between IL-17 vs. Th17 cells and cancer patient survival: a systematic review

et al. 2015

View full text Add to dashboard Cite

Both IL-17 and Th17 cells have been ascribed tumor promoting as well as tumor suppressing functions. We reviewed the literature on correlations between IL-17 versus Th17 cells and survival in human cancer, following the PRISMA guidelines. Serum, formalin-fixed, paraffin-embedded (FFPE) tissue and peripheral blood samples were most frequently studied. High IL-17 quantities were correlated with poor prognosis, whereas high Th17 cell frequencies were correlated with improved prognosis. Since Th17 cells are a subpopulation of IL-17 cells and had a different correlation with prognosis than total IL-17, we substantiate that a distinction should be made between Th17 and other IL-17 cells.

show abstract

Section: Study Design and Selection Criteriamentioning

confidence: 94%

The correlations between IL-17 vs. Th17 cells and cancer patient survival: a systematic review

et al. 2015

View full text Add to dashboard Cite

show abstract

“…Moreover, retrospectively and irrespective of bevacizumab therapy, Tosolini et al [38] showed that colorectal cancer patients with high expression of the Th17 genes cluster, analyzed from frozen specimens, had a poor prognosis and this result was confirmed with the quantification of IL-17-positive cells in situ. To date, only one team reported that high IL-17A expression, compared to expression in adenoma and non-tumor tissue, is an independent favorable prognostic factor that predicts overall survival of colorectal cancer by quantifying RNA expression in tissues and IL-17A immunohistochemical levels [39]. All the other publications reported that IL-17A high expression (RNA, immunohistochemistry and/or serum concentration) is a negative prognostic marker of colorectal cancer progression [8, 9, 38, 40].…”

Section: Discussionmentioning

confidence: 99%

A possible association of baseline serum IL-17A concentrations with progression-free survival of metastatic colorectal cancer patients treated with a bevacizumab-based regimen

et al. 2017

View full text Add to dashboard Cite

BackgroundColorectal cancer is a major public health issue worldwide. Interleukin-17 (IL-17) and Th17 (T-helper cell type 17)-related molecules are involved in tumor development and in resistance to bevacizumab, an anti-vascular endothelial growth factor monoclonal antibody used in association with chemotherapy in metastatic colorectal cancer. Some studies have previously shown that IL-17A and IL-17F polymorphisms, respectively rs2275913 and rs763780, are associated with gastric or colorectal cancer risk. Here we aimed at studying the influence of IL-17A-related individual factors on overall survival and progression-free survival in patients with metastatic colorectal cancer treated with a bevacizumab-based chemotherapy.MethodsPre-treatment serum biomarkers were retrospectively evaluated in 122 metastatic colorectal cancer patients treated by bevacizumab in combination with chemotherapy at 2-weeks intervals in a prospective cohort study (NCT00489697). The polymorphisms of IL-17A and IL-17F were analyzed by polymerase chain reaction - restriction fragment length polymorphism. Serum concentrations of Th17-related cytokines were measured by MultiPlex. The impact of individual parameters on overall survival and progression-free survival was assessed using multivariate Cox models.ResultsHigh baseline IL-17A serum concentrations were significantly associated with shorter progression-free survival [p = 0.043]. Other baseline serum Th17-related cytokines and polymorphisms of IL-17 were not associated with overall survival or progression-free survival.ConclusionsIn this ancillary study, baseline serum IL-17A concentration is the only Th17/IL-17 related factor that was significantly associated with the response of patients with metastatic colorectal cancer to bevacizumab. But this main significant result is highly dependent on one case which, if left out, weakens the data. Other clinical studies are required to confirm this association.Trial registration NCT00489697. June 20, 2007.

show abstract

“…As shown in Fig 2.A, the relevance between high level of IL-17 + cells and histological grade (poor differentiation versus (vs.) well/moderate differentiation) was evaluated in 14 studies including head and neck cancers (HNC) (n = 2) [38,39], breast cancer (n = 1) [17], non-small-cell lung cancer (NSCLC) (n = 2) [40,41] and cancers of digestive system (n = 9) [16,20,28,[42][43][44][45][46][47], with 1645 patients. Results showed no statistical significance was found between high level of IL-17 + cells and histological grade (RR = 1.10, 95% CI [0.90, 1.34]).…”

Section: Il-17 + Cells and Histological Gradementioning

confidence: 99%

“…The association between high IL-17 + cells and lymph node metastasis was explored in 9 studies with 1074 patients [17,20,38,[42][43][44][45][46]48] (Fig 2.B). RR for the relevant 9 studies was 0.97 (95% CI [0.81, 1.15]), indicating the high IL-17 + cells within tumor tissues had no significant influence on lymph node status.…”

Section: Il-17 + Cells and Lymph Node Metastasismentioning

confidence: 99%

“…We further analyzed the impact of IL-17 + cells on distant metastasis (Fig 3.C) and tumor recurrence (Fig 3.D). Pooled RR of 6 studies with 602 patients showed a non-statistically significant correlation between high IL-17 + cells and distant metastasis (RR = 1.36, 95%CI [0.70, 2.63]) [38,39,42,44,46,49]. Moreover, 4 studies with 317 patients investigated the correlation between high IL-17 + cells and tumor recurrence [38,39,44,49].…”

Section: Distant Metastasis and Tumor Recurrencementioning

confidence: 99%

See 1 more Smart Citation

Prognostic significances of interleukin-17-producing cells and Th17 cells in malignant cancers: a meta-analysis of the literatures

Luo

Takata

et al. 2019

Preprint

View full text Add to dashboard Cite

Background and purposeAs a proinflammatory factor, interleukin-17 (IL-17) can play a role in both tumor promotion and suppression. IL-17 is traditionally regarded as secreting mainly by CD4 + T helper cells (Th17 cells), while other immune subsets have been proved to produce IL-17, called IL-17 + cells. Considerable studies have drawn controversial conclusions about association between IL-17 + /Th17 cells and prognosis of cancer patients. This meta-analysis was performed to systematically and quantitatively analyze prognostic values of IL-17 + cells and Th17 cells in cancer patients. MethodsA comprehensive retrieval was conducted in Pubmed (MEDLINE) and EMBASE databases. Pooled risk ratios (RRs) or hazard ratios (HRs) and corresponding 95% confidence intervals (CI) were calculated to evaluate the prognostic values of IL-17 + cells and Th17 cells in cancer patients. ResultsA total of 42 studies with 5039 patitents were included. High IL-17 + cells was significantly associated with tumor recurrence (RR = 4.23, 95% CI [1. 58, 11.35]), worse disease free survival (DFS) (HR = 1.84, 95% CI [1.22, 2.77]) and overall survival (OS) (HR = 1.39, 95% CI [1.04, 1.87]), especially in cancers of digestive system. Besides, no significant difference was observed between high IL-17 + cells Prognostic values of IL-17 + /Th17 cells in cancers: a meta-analysis 3 and histological grade, lymph node metastasis, tumor volume, clinical stages or distant metastasis. Moreover, there was no significant difference in OS between high and low Th17 cells in cancer patients (HR = 0.93, 95% CI [0.58, 1.49]). ConclusionsThis meta-analysis suggests high IL-17 + cells could be an indicator for worse survival in patients with malignant cancers, especially with cancers of digestive system.Although high Th17 cells appears to have non-statistically significance on prognosis, more clinical studies should be implemented to investigate the underlying function of Th17 cells within tumor microenvironment. This study put forward a new insight for potential application of anti-IL-17 target therapy in cancer therapeutics.

show abstract

Interleukin-17 is a favorable prognostic marker for colorectal cancer

Abstract: The association between IL-17 expression and the clinicopathological parameters, as well as the clinical outcome suggests a significant role of IL-17 in CRC. IL-17 is a marker of favorable prognosis.

Cited by 48 publications

References 33 publications

The correlations between IL-17 vs. Th17 cells and cancer patient survival: a systematic review

The correlations between IL-17 vs. Th17 cells and cancer patient survival: a systematic review

A possible association of baseline serum IL-17A concentrations with progression-free survival of metastatic colorectal cancer patients treated with a bevacizumab-based regimen

Prognostic significances of interleukin-17-producing cells and Th17 cells in malignant cancers: a meta-analysis of the literatures

Contact Info

Product

Resources

About